Another possible explanation for the discrepancy between our results in primary T cells and the previous data in tumor cell lines is that during development, the Drak2-/- T cells may have compensated for the loss of Drak2 through modifications of alternate pathways involved in TGF-β regulation. This evidence concerns the gene TGFB1 and neoplasm.